SCHEMBL328174

SCHEMBL328174

O=C(O)C1=CN(Cc2ccccc2)CCc2c1[nH]c1ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.47
NR1H4 Q96RI1 4/20 0.45
GPX4 P36969 1/20 0.44
HDAC6 Q9UBN7 4/20 0.43
HDAC1 Q13547 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
HSD17B10 Q99714 2/20 0.43
PDE5A O76074 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274504 0.85 NR1H4 (0.62) NR1H4KDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL13703543 0.81 ACHE (0.46) ACHEGPX4HDAC6HDAC1KDM4E
SCHEMBL274721 0.79 NR1H4 (0.51) NR1H4GPX4HDAC6KDM4EALDH1A1
SCHEMBL272586 0.78 NR1H4 (0.61) NR1H4HDAC6KDM4EALDH1A1SMN1; SMN2
SCHEMBL5732150 0.75 NR1H4 (0.47) NR1H4GPX4HDAC6KDM4EALDH1A1
SCHEMBL275620 0.75 NR1H4 (0.56) NR1H4KDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL274792 0.75 TRPV1 (0.57) NR1H4HDAC6KDM4EALDH1A1SMN1; SMN2
SCHEMBL273500 0.73 NR1H4 (0.73) NR1H4POLBMTHFD2
SCHEMBL29881430 0.73 NR1H4 (0.73) NR1H4POLBMTHFD2
SCHEMBL5732372 0.73 NR1H4 (0.49) NR1H4GPX4HDAC6HDAC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133992-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2012-03-13 US disclosed
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2010-07-08 US disclosed
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents EXELIXIS, INC. (US) 2009-12-31 US disclosed
US-7485634-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2009-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents HTR2A, HTR5A, HTR2C ACHE 381/4885NR1H4 253/4885GPX4 2077/4885
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents HTR5A, MTNR1A, PTGDR ACHE 409/4885NR1H4 268/4885GPX4 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.